$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[국내논문] 다낭성 난소증후군의 과배란유도시 GnRH Antagonist (Cetrorelix)를 병합한 Minimal Stimulation Protocol의 임상적 유용성에 관한 연구
A Study for Clinical Efficacy of GnRH Antagonist (Cetrorelix) Minimal Stimulation Protocol in Assisted Reproductive Techniques for Polycystic Ovaian Syndrome 원문보기

대한불임학회지 = Korean journal of fertility and sterility, v.29 no.4, 2002년, pp.251 - 258  

박성대 (중앙대학교 의과대학 산부인과학교실) ,  이상훈 (중앙대학교 의과대학 산부인과학교실)

Abstract AI-Helper 아이콘AI-Helper

Objective : The aim of this study was to evaluate the outcomes of the GnRH antagonist (Cetrotide) minimal stimulation protocol comparing with GnRH agonist combined long step down stimulation protocol in PCOS patients. Materials and Method: From Apr 2001 to May 2002, 22 patients (22 cycles) were perf...

Keyword

참고문헌 (28)

  1. Tummon IS, Daniel SAJ, Kaplan BR, Nisker JA, Yuzpe AA. Randomized, prospective comparison of luteal leuprolide acetate and gonadotropins versus clomiphene citrate and gonadotropins in 408 first cycles of in vitro fertilizatin. Fertil Steril 1992; 58:563-8 

  2. Poter RN, Smith W, Craft IL. Induction of ovulation for in vitro fertilization using buserelin and gonadotropins. Lancet II 1984; 1284-5 

  3. Albrecht JL, Tomich PG. The maternal and neonatal outcome of triple gestations. American Journal of Obstetrics and Gynecology 1996; 174: 1551-6 

  4. Judith AF Huirne, Cornelis B Lambalk. Gonadotropin-releasing-hormone-receptor antagonists. The Lancet 2001; 358: 1793-803 

  5. Olivennes F, Fanchin R, Bouchard P, et al. The single or dual administration of the gonadotrophin-releasing hormone antagonist Cetrorelix is an in vitro fertilization-embryo transfer programme. Fertil Steril 1994; 62: 468-76 

  6. Albano C, Riethmuller-Winzen H, Smitz J, Van Steirteghem A, Camus M, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997;67;5:917-22 

  7. Smitz J, Camus M, Devroey P. Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in vitro fertilization. Hum Reprod 1990; 5: 933-40 

  8. Graft I, Gorgy A, Jennifer H, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols? 1999; 12(22): 2959-62 

  9. Andreyko JL, Marshall LA, Dumesic DA, Jaffe RB. Therapeutic uses of gonadotropin-releasing hormone analogs. Obstet Gynecol Surv 1987; 42: 1-21 

  10. Albano C, Platteau P, Devroey P. Gonadotropin releasing hormone antagonist: how good is the new hope? Curr Opin Obstet Gynecol 2001; 13: 257-62 

  11. Albano C, Felberbaum R, Smitz J, et al. On behalf of the European Cetrorelix Study Group. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 2000; 3: 526-31 

  12. Elchalal U, Schenken JG. The pathophysiology of ovarian hyperstimulation syndrome - views and ideas. Hum Reprod 1997; 12: 1129-37 

  13. Egbase PE, Sharhan M, Grudzinskas J. 'Early coasting' in patients with polycystic ovarian syndrome is consistent with good clinical outcome. Hum Reprod 2002; 17: 1212-6 

  14. Ulug U, Bahceci M, Erden H, Shalev E, Ben-Shlomo I. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 2002; 17(2):310-3 

  15. Demetrios M, Michael MA, Selwyn PO, Susan ML, Joseph FM, Spyros NP. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: Cycle performance and in vitro steroidogenesis of granulosa-lutein cells. American Journal of Obstetrics and Gynecology 1995; 172(5): 1518-25 

  16. Hoff JD, Lasley BL, Yen SSC. The functional relationship between priming and releasing actions of luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 1979; 49: 8-15 

  17. Yen SSC. The polycystic ovarian disease. Clin Endocrinol (Oxford) 1980; 12: 177-207 

  18. Yen SSC, Jaffe RB. Reproduction. Endocrinology 3rd Ed, Philadelpia, WB Saunders 1991; 593-7 

  19. Falcone T, Bourque J, Granger L, Hemmings R, Miron P. Polycystic ovary syndrome. Current Roblems Obset Gynecol Fertil 1993; 16: 72-89 

  20. Gysler MG, March CM, Mishell DR, Gailey EJ. A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril 1982;37: 161-7 

  21. Chung-hoon Kim, Hee-done C, Eun-hee K, Hyung-sik C, Byund-moon K, Yoon-seok C. The effects of somatostatin analogue on ovarian response to ovulation induction in patients with polycystic ovarian syndrome. 대한산부회지 1999; 42(3): 496-503 

  22. Ben-Rafael Z, Strauss JF Ill, Mastroianni L Jr, Flickinger GL. Differences in ovarian stimulation in human menopausal gonadotropin treated woman may be related to follicle-stimulating hormone accumulation. Fertil Steril 1986; 46: 586-92 

  23. Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosler A, et al. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 1987;48:57-61 

  24. Wu TCJ, Gelety TH, Jih MH, Fournet N, Buyalos RP. Successful management of predicted severe ovarian hyperstimulation syndrome with gonadotropin-releasing hormone agonist. J Assist Reprod Genet 1992; 622-4 

  25. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991; 56:213-20 

  26. Urman B, Pride SM, Yuen BH. Management of overstimulated gonadotrophin cycles with a controlled drift period. Hum Reprod 1992; 7: 918-22 

  27. Hall JE. Gonadotropin-releasing hormone antagonists: Effects on the ovarian follicle and corpus luteum. Clin Obstet Gynecol 1993; 36:744-52 

  28. Borm G, Mannaerts B. The European Orgalutran Study Group. Treatment with the gonadotrophin releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000; 15: 1490-8 

활용도 분석정보

상세보기
다운로드
내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

관련 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로